TrialAnnals of the rheumatic diseases2017

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.

Maxime Dougados et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.